X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Edelweiss Financial - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs EDELWEISS FINANCIAL - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

EDELWEISS FINANCIAL 
   Change

Edelweiss is among the larger institutional brokerage firms in India, with a strong domestic investment-banking business. It has a good market share in the institutional broking, and strong presence in derivatives. While its strengths remain in priva... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES EDELWEISS FINANCIAL INDOCO REMEDIES/
EDELWEISS FINANCIAL
 
P/E (TTM) x 38.2 20.4 187.0% View Chart
P/BV x 3.0 3.0 101.0% View Chart
Dividend Yield % 0.8 0.5 139.8%  

Financials

 INDOCO REMEDIES   EDELWEISS FINANCIAL
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
EDELWEISS FINANCIAL
Mar-18
INDOCO REMEDIES/
EDELWEISS FINANCIAL
5-Yr Chart
Click to enlarge
High Rs360309 116.5%   
Low Rs249157 158.9%   
Sales per share (Unadj.) Rs119.093.7 127.0%  
Earnings per share (Unadj.) Rs8.49.7 86.0%  
Cash flow per share (Unadj.) Rs15.210.9 139.2%  
Dividends per share (Unadj.) Rs1.601.35 118.5%  
Dividend yield (eoy) %0.50.6 90.7%  
Book value per share (Unadj.) Rs70.772.9 97.0%  
Shares outstanding (eoy) m92.15915.50 10.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.5 103.0%   
Avg P/E ratio x36.424.0 152.0%  
P/CF ratio (eoy) x20.021.3 93.9%  
Price / Book Value ratio x4.33.2 134.7%  
Dividend payout %19.113.9 137.8%   
Avg Mkt Cap Rs m28,083213,403 13.2%   
No. of employees `0006.010.1 60.0%   
Total wages/salary Rs m2,16713,549 16.0%   
Avg. sales/employee Rs Th1,817.08,536.6 21.3%   
Avg. wages/employee Rs Th359.01,347.9 26.6%   
Avg. net profit/employee Rs Th127.7885.5 14.4%   
INCOME DATA
Net Sales Rs m10,96885,810 12.8%  
Other income Rs m40376 10.6%   
Total revenues Rs m11,00786,186 12.8%   
Gross profit Rs m1,56550,218 3.1%  
Depreciation Rs m6331,117 56.7%   
Interest Rs m6235,295 0.2%   
Profit before tax Rs m90914,182 6.4%   
Minority Interest Rs m0278 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1395,599 2.5%   
Profit after tax Rs m7718,901 8.7%  
Gross profit margin %14.358.5 24.4%  
Effective tax rate %15.339.5 38.6%   
Net profit margin %7.010.4 67.7%  
BALANCE SHEET DATA
Current assets Rs m5,725385,999 1.5%   
Current liabilities Rs m5,454260,489 2.1%   
Net working cap to sales %2.5146.3 1.7%  
Current ratio x1.01.5 70.8%  
Inventory Days Days62689 9.0%  
Debtors Days Days72112 64.3%  
Net fixed assets Rs m5,3077,538 70.4%   
Share capital Rs m184916 20.1%   
"Free" reserves Rs m6,33165,791 9.6%   
Net worth Rs m6,51666,706 9.8%   
Long term debt Rs m1,323273,061 0.5%   
Total assets Rs m11,970635,135 1.9%  
Interest coverage x15.61.4 1,116.0%   
Debt to equity ratio x0.24.1 5.0%  
Sales to assets ratio x0.90.1 678.2%   
Return on assets %7.07.0 100.0%  
Return on equity %11.813.3 88.6%  
Return on capital %12.414.7 84.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,507190 2,375.3%   
Fx outflow Rs m1,14157 2,015.5%   
Net fx Rs m3,366133 2,528.4%   
CASH FLOW
From Operations Rs m886-111,375 -0.8%  
From Investments Rs m-1,706-23,283 7.3%  
From Financial Activity Rs m1,316148,346 0.9%  
Net Cashflow Rs m49713,508 3.7%  

Share Holding

Indian Promoters % 59.2 37.3 158.7%  
Foreign collaborators % 0.0 0.1 -  
Indian inst/Mut Fund % 12.5 0.0 -  
FIIs % 6.0 21.1 28.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 41.5 54.0%  
Shareholders   12,805 134,647 9.5%  
Pledged promoter(s) holding % 0.0 52.2 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   CCL INTERNATIONAL  THOMAS COOK INDIA  MIC ELECTRONICS  MOTILAL OSWAL  REPCO HOME  



Today's Market

Sensex Remains Rangebound; HDFC AMC & Reliance Nippon Tumble Over 8%(12:30 pm)

Stock markets in India are trading in a range with positive bias in the afternoon session amid firm cues in the Asian markets and a recovery in rupee. Gains are largely seen in metal stocks and energy stocks.

Related Views on News

EDELWEISS FINANCIAL Announces Quarterly Results (1QFY19); Net Profit Up 31.2% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, EDELWEISS FINANCIAL has posted a net profit of Rs 3 bn (up 31.2% YoY). Sales on the other hand came in at Rs 24 bn (up 29.0% YoY). Read on for a complete analysis of EDELWEISS FINANCIAL's quarterly results.

EDELWEISS FINANCIAL Announces Quarterly Results (4QFY18); Net Profit Up 72.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, EDELWEISS FINANCIAL has posted a net profit of Rs 2 bn (up 72.6% YoY). Sales on the other hand came in at Rs 26 bn (up 35.2% YoY). Read on for a complete analysis of EDELWEISS FINANCIAL's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 19, 2018 01:09 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - GEOJIT FINANCIAL SERVICES COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS